Jacobs Levy Equity Management, Inc Fate Therapeutics Inc Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q1 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 2,203,323 shares of FATE stock, worth $2.62 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,203,323
Previous 1,586,987
38.84%
Holding current value
$2.62 Million
Previous $2.62 Million
33.54%
% of portfolio
0.01%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding FATE
# of Institutions
144Shares Held
97MCall Options Held
56.7KPut Options Held
5.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$15.3 Million1.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$12.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$12 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY7.79MShares$9.28 Million0.04% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.29MShares$5.1 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $115M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...